Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: A potential therapeutic approach to EBV-associated lymphoproliferative diseases

European Journal of Haematology

Volumn 80, Issue 5, 2008, Pages 407-418

  Srimatkandada, Pavani ^a,b   Loomis, Regina ^a,b   Carbone, Rocco ^b   Srimatkandada, Srinivasan ^a,b   Lacy, Jill ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Apoptosis; Bcl 2; Bortezomib; Epstein Barr virus; Lymphoproliferative disease; Proteasome

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOBLASTOID CELL; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

APOPTOSIS; BENZOPYRANS; BORONIC ACIDS; CASPASES; CELL LINE, TRANSFORMED; CELL PROLIFERATION; ENZYME ACTIVATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTES; LYMPHOPROLIFERATIVE DISORDERS; NITRILES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZINES;

EID: 41849083758     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01044.x     Document Type: Article

References (36)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In : Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Fields Virology, 4th edn. Philadelphia : Lippincott/The Williams & Wilkins Co, 2001 : 2575 627.
2. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In : Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Fields Virology, 4th edn. Philadelphia : Lippincott/The Williams & Wilkins Co, 2001 : 2511 74.
3. Farrell PJ. Signal transduction from the Epstein-Barr virus LMP-1 transforming protein. Trends Microbiol 1998 6 : 175 8.
4. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991 65 : 1107 15.
5. Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 1997 94 : 12592 7.
6. Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF, Kieff E. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998 72 : 7900 8.
7. Atkinson GP, Coope HJ, Rowe M, Ley SC. Latent membrane protein 1 of Epstein-Barr virus stimulates processing of NF-kB2 p100 to p52. J Biol Chem 2003 51 : 51134 42.
8. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 1992 267 : 24157 60.
9. Rowe M, Peng-Pilon M, Huen DS, Hardy R, Croom-Carter D, Lundgren E, Rickinson AB. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 1994 68 : 5602 12.
10. Feuillard J, Schuhmacher M, Kohanna S, Asso-Bonnet M, Ledeur F, Joubert-Caron R, Bissieres P, Polack A, Bornkamm GW, Raphael M. Inducible loss of NF-kappaB activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes. Blood 2000 95 : 2068 75.
11. Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, Kieff E. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 2004 78 : 4108 19.
12. D'Souza BN, Edelstein LC, Pegman PM, Smith SM, Loughran ST, Clarke A, Mehl A, Rowe M, Gelinas C, Walls D. Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. J Virol 2004 78 : 1800 16.
13. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 2000 97 : 6055 60.
14. Guinness ME, Kenney JL, Reiss M, Lacy J. Bcl-2 anti-sense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Res 2000 60 : 5354 8.
15. Loomis R, Carbone R, Reiss M, Lacy J. Bcl-2 anti-sense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab. Clin Cancer Res 2003 9 : 1931 9.
16. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003 9 : 6316 25.
17. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the non-canonical NF-kB pathway in multiple myleoma. Cancer Cell 2007 12 : 131 44.
18. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Ann Rev Medicine 2006 57 : 33 47.
19. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001 61 : 3071 6.
20. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002 99 : 14374 9.
21. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003 171 : 88 95.
22. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003 278 : 33714 23.
23. Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R, Munshi N, Richardson P, Cotter FE, Anderson KC. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 2004 104 : 2458 66.
24. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000 97 : 7124 9.
25. An J, Chen Y, Huang Z. Critical upstream signals of cytochrome C release induced by a novel Bcl-2 inhibitor. J Biol Chem 2004 279 : 19133 40.
26. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984 22 : 27 55.
27. Yamaguchi H, Wang H-G. Bcl-XL protects BimEL-induced conformation change and cytochrome C release independent of interacting with Bax or BimEL. J Biol Chem 2002 277 : 41604 12.
28. Dewson G, Snowden RT, Almond JB, Dyer MJ, Cohen GM. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene 2003 22 : 2643 54.
29. Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J, Jiang JD, Muggia FM, Perez-Soler R. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002 1 : 841 9.
30. Duechler M, Shehata M, Schwarzmeier JD, Hoelbl A, Hilgarth A, Hubmann R. Induction of apoptosis by proteasome inhibitors in B-CLL is associated with downregulation of CD23 and inactivation of Notch2. Leukemia 2005 19 : 260 7.
31. Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J Biol Chem 2002 277 : 11617 20.
32. Juin P, Hueber AO, Littlewood T, Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome C release. Genes Devel 1999 13 : 1367 81.
33. Juin P, Hunt A, Littlewood T, Griffiths B, Swigart LB, Korsmeyer S, Evan G. c-Myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol 2002 22 : 6158 69.
34. Shiio Y, Suh KS, Lee H, Yuspa SH, Eisenman RN, Aebersold R. Quantitative proteomic analysis of myc-induced apoptosis: a direct role for Myc induction of the mitochondrial chloride ion channel, mtCLIC/CLIC4. J Biol Chem 2006 281 : 2750 6.
35. Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003 17 : 2036 45.
36. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 2005 106 : 408 18.